8-K: Predictive Oncology Recasts Financials Amid Strategic Shift to AI-Driven Drug Discovery and Proposed Merger

Predictive Oncology Inc. has retrospectively revised its 2024 financial statements to reflect the divestment of its Eagan business as discontinued operations, while pursuing a merger with Renovaro Inc. and focusing on its core AI-driven oncology drug discovery.

Summary

• Predictive Oncology Inc. (POAI) filed a Form 8-K to retrospectively revise and recast its historical consolidated financial statements for the fiscal year ended December 31, 2024, and 2023, to present the Eagan Business as discontinued operations.
• The Eagan Business, which included the STREAMWAY product line for automated medical fluid disposal, was sold to DeRoyal Industries, Inc. on March 14, 2025.
• The company's Birmingham laboratory business, providing contract services and research, was also discontinued in the third quarter of 2024.
• Predictive Oncology's continuing operations are now solely focused on its Pittsburgh-based business, which applies artificial intelligence (AI) to support the discovery and development of optimal cancer therapies, utilizing its proprietary biobank of over 150,000 tumor samples and 3D cell culture models.
• The company reported a net loss of $12,664,388 for the year ended December 31, 2024, compared to $13,983,967 in 2023.
• Revenue from continuing operations significantly decreased to $84,812 in 2024 from $492,596 in 2023, primarily due to decreased sales of 3D tumor-specific models.
• The gross profit margin for continuing operations declined to 8% in 2024 from 60% in 2023.
• As of December 31, 2024, the company had cash and cash equivalents of $611,822 and an accumulated deficit of $180,426,271.
• Net cash used in continuing operating activities was $10,103,084 in 2024.
• Substantial doubt exists about the company's ability to continue as a going concern due to recurring losses and the need for significant additional capital.
• The company is pursuing a proposed merger with Renovaro, Inc. (RENB), where Predictive Oncology shareholders would receive a newly created series of Renovaro preferred stock in a 1:1 exchange for their common stock, redeemable at $3.00 per share after 18 months or convertible to Renovaro common stock at a 1:1 ratio if Renovaro's common stock trades at or above $4.50 for 30 consecutive days.
• The Renovaro merger is subject to a minimum fundraising of $15 million by Renovaro and formal approval by Predictive Oncology shareholders.
• Recent funding activities include $3.58 million net proceeds from a May 2024 at-the-market offering, $1.0 million net proceeds from a July 2024 warrant inducement transaction, $545,004 gross proceeds from a February 2025 registered direct offering, $500,000 from Renovaro's purchase of shares in March 2025, and $1.3 million from warrant exercises in March 2025.
• The company regained compliance with NASDAQ's minimum bid price requirement on January 22, 2025, but remains non-compliant with the minimum stockholders' equity requirement as of November 20, 2024, with a plan submitted to NASDAQ.

Sentiment

Score: 3

Explanation: While the company is making strategic shifts and has secured some recent funding, the severe and recurring net losses, accumulated deficit, negative cash flow from continuing operations, and explicit 'going concern' doubt indicate a very challenging financial position. The significant decline in continuing operations revenue and gross profit margin further underscore the negative financial performance, despite the strategic focus on AI in oncology.

Positives

• The company is strategically focusing its business on AI-driven oncology drug discovery and 3D cell culture models, a high-growth and innovative sector.
• Divestment of the non-core Eagan business (STREAMWAY product line) allows for a more concentrated focus on the core oncology business.
• Successfully raised capital through multiple financing activities, including a May 2024 ATM offering ($3.58 million net), a July 2024 warrant inducement transaction ($1.0 million net), a February 2025 registered direct offering ($545,004 gross), and March 2025 warrant exercises ($1.3 million).
• The sale of the Eagan Business generated $625,000 in cash proceeds plus assumed liabilities.
• Regained compliance with NASDAQ's minimum bid price requirement on January 22, 2025.
• The proposed merger with Renovaro, Inc. could provide a strategic path forward and potential liquidity for existing shareholders through preferred stock.

Negatives

• The company incurred significant and recurring net losses, with $12,664,388 in 2024 and $13,983,967 in 2023.
• An accumulated deficit of $180,426,271 as of December 31, 2024, highlights a history of unprofitability.
• Revenue from continuing operations decreased substantially to $84,812 in 2024 from $492,596 in 2023, indicating a significant decline in core business sales.
• The gross profit margin for continuing operations sharply declined to 8% in 2024 from 60% in 2023.
• Negative cash flows from continuing operating activities amounted to $10,103,084 in 2024.
• Substantial doubt exists about the company's ability to continue as a going concern, necessitating significant additional capital.
• The company is non-compliant with NASDAQ's minimum stockholders' equity requirement, with stockholders' equity at a deficit of $(202,610) as of December 31, 2024, down from $8,271,780 in 2023.
• Future revenues are expected to materially decline due to the divestment of the Eagan segment, which previously contributed a substantial portion of total revenues.
• Future financing alternatives may result in significant dilution to existing stockholders or loss of investment.
• If the Renovaro merger fails after Renovaro's prior funding, Predictive Oncology will be obligated to provide Renovaro a two-year exclusive royalty-free license to its biobank and 3D cell culture models.

Risks

• Ability to continue operations beyond twelve months is dependent on obtaining additional financing.
• Continued negative operating cash flows pose a significant challenge to financial sustainability.
• Future capital needs may lead to highly dilutive equity financing or debt with onerous terms.
• Risks associated with the success of collaboration arrangements, commercialization activities, and product sales levels by partners.
• Inability to protect intellectual property or potential claims of infringing on others' intellectual property.
• Impact of intense competition in the biopharmaceutical and drug discovery markets.
• Challenges in acquiring and maintaining necessary regulatory clearances for technology applications.
• Difficulty in attracting or retaining qualified senior management, sales, and marketing personnel.
• Risk of never achieving profitability if products and services are not widely accepted by potential customers.
• Potential adverse impact of government regulation and scrutiny on business operations.
• Exposure to unexpected costs, operating deficits, and lower than expected sales and revenues.
• Adverse results from any legal proceedings.
• Volatility of operating results and financial condition.
• Challenges associated with managing growth effectively.
• Business and operations could be materially and adversely affected by disruptions from economic and geopolitical uncertainties, including inflation, rising interest rates, supply chain issues, tight labor markets, and global conflicts.
• Reliance on sole suppliers for certain molecular diagnostic test materials and reagents could lead to delays and interruptions if supply is disrupted.
• Uncertainty regarding the availability of future funding under acceptable terms, which could force the company to limit business activities, default on obligations, or cease operations.
• The proposed merger with Renovaro, Inc. is subject to conditions, including a minimum fundraising of $15 million by Renovaro and formal approval by Predictive Oncology shareholders, with no assurance of completion.
• The company's net operating loss (NOL) carryforwards may be further limited by future issuances of common stock under Section 382 of the Internal Revenue Code.

Future Outlook

The company expects its revenues in future periods to materially decline due to the divestment of the Eagan segment. It continues to evaluate alternatives to obtain the required additional funding to maintain future operations, including the proposed merger with Renovaro, Inc. The company believes its AI-driven platform and biobank offer unique advantages to accelerate drug discovery and improve clinical success probability, aiming to improve the way the biopharma industry develops oncology drugs.

Management Comments

• "By harnessing the power of machine learning and scientific rigor, we believe that we can improve the probability of success of advancing pharmaceutical and biological drug candidates with a higher degree of confidence."
• "We believe leveraging our unique, historical database of tumor drug responses, genomics, biomarkers, digitized pathology slides, and histopathology data with over 150,000 patient tumor samples to efficiently build AI driven predictive models of tumor drug response will provide actionable insights critical to new drug development."
• "We believe this patient-derived, highly curated, multi-omic tumor model offers a better chance of generating predictive models of drug-response and outcomes than competitive approaches in the market today."
• "We believe our platform provides unique financialand time-saving advantages for pharmaceutical companies."
• "We believe that to maintain a competitive advantage in the marketplace, we must develop and maintain protection of the proprietary aspects of our technology."
• "We believe our relations with our employees are satisfactory."

Industry Context

The company operates within the growing market for AI-empowered solutions in drug discovery, driven by the demand for improved efficiency, reduced cycle times, and increased accuracy in the drug development process. The adoption of AI solutions is fueled by growing partnerships and cooperation in the global market. The FDA Modernization Act 2.0 is expected to increase the use of non-animal methods for drug development, such as cell-based assays and computer models, which aligns with the company's focus on 3D modeling and AI-driven predictions. The company aims to leverage its PEDAL platform to help biopharma clients prioritize their oncology portfolios and improve the development of oncology drugs.

Comparison to Industry Standards

• The company believes no other company has access to a comparable privately held biobank with tumor drug responses, genomics, biomarkers, digitized pathology slides, and histopathology data, providing a competitive advantage and barrier to entry in drug response prediction.
• The company's patient-derived, highly curated, multi-omic tumor model is believed to offer a better chance of generating predictive models of drug-response and outcomes than competitive approaches currently in the market.
• The STREAMWAY System, which was divested, was described as the only known automated fully closed direct-to-drain system that is wall-mounted and able to collect, measure, and dispose of an unlimited amount of waste fluid without interruption.

Corporate Governance

Related Party Transactions

• Renovaro, Inc. acquired 467,290 shares of Predictive Oncology's common stock for $500,000 in March 2025, as part of the Extension Agreement related to the proposed merger. Renovaro also agreed to purchase an additional 901,298 shares for $964,389 upon execution of a definitive merger agreement.

Stakeholder Impact

• **Shareholders**: Face potential significant dilution from future capital raises and the proposed merger. The merger offers a potential exit strategy with preferred stock, but also risks if the merger conditions are not met or if the company cannot continue as a going concern, potentially leading to loss of investment.
• **Employees**: Experienced headcount reductions, contributing to decreased employee-related expenses. The strategic shift to AI-driven oncology may impact future staffing needs and skill requirements.
• **Customers**: The company's focus on AI-driven drug discovery and 3D models aims to provide enhanced solutions for biopharmaceutical clients, potentially improving drug development efficiency and success rates.
• **Creditors**: The company's 'going concern' doubt and significant accumulated deficit indicate a heightened risk for creditors, with a possibility of default on existing payment obligations if adequate funding is not secured.
• **Suppliers**: The company relies on sole suppliers for certain molecular diagnostic test materials, posing a risk of interruption if these suppliers are lost or materials do not meet quality specifications.

Next Steps

• Renovaro, Inc. needs to raise a minimum of $15 million for the proposed merger to proceed.
• Predictive Oncology shareholders must formally approve the proposed merger with Renovaro, Inc.
• Upon execution of a definitive merger agreement, Renovaro, Inc. is committed to purchasing an additional 901,298 shares of Predictive Oncology common stock for $964,389.
• The company will continue to evaluate alternatives to obtain the required additional funding to maintain future operations.
• The company plans to adopt ASU 2023-07 for interim periods beginning in the fiscal year ending December 31, 2025.
• Management is currently evaluating ASU 2023-09 and ASU 2024-03 to determine their impact on the company's disclosures.

Key Dates

Recommendation

Keywords

Predictive Oncology, POAI, SEC filing, 8-K, discontinued operations, financial restatement, AI, artificial intelligence, oncology, drug discovery, cancer therapies, biobank, 3D cell culture models, STREAMWAY System, medical fluid disposal, DeRoyal Industries, Renovaro, merger, capital raise, going concern, NASDAQ compliance, financial results, net loss, revenue, cash flow